Resmed (RSMDF) Cost of Revenue (2009 - 2026)

Resmed (RSMDF) has reported Cost of Revenue for 18 consecutive years, with $602.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 14.11% year-over-year to $602.4 million; the trailing twelve-month figure through Jun 2026 stood at $2.2 billion (up 5.28% YoY), and the FY2026 full-year result was $2.2 billion, up 5.28% from the prior year.
• Cost of Revenue climbed to $602.4 million in Q2 2026 per RSMDF's latest filing, from $540.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $602.4 million in Q2 2026 and bottomed at $373.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $497.6 million across 5 years, with a median of $507.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue soared 33.71% in 2023, then increased 0.59% in 2024.
• Over 5 years, Cost of Revenue stood at $454.0 million in 2022, then increased by 13.62% to $515.9 million in 2023, then gained by 2.9% to $530.8 million in 2024, then increased by 2.5% to $544.1 million in 2025, then climbed by 10.72% to $602.4 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $602.4 million, $540.4 million, and $544.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.